Crescent Biopharma, Inc. Stock: price and insider trades · United States

Every trade that managers of Crescent Biopharma, Inc. disclose to SEC (Form 4) is tracked on this page. 11 insiders have disclosed 30 filings since 18 October 2025.

Open-market activity splits into 2 purchases totalling €26.4M and 16 sales totalling €248k; 1 insider sit on the buying side and 7 insiders on the selling side. The totals exclude 7 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Fairmount Funds Management LLC filed the largest purchase, €15.6M, on 8 December 2025. Those buying include 1 senior executive.

The latest purchase dates back some time: it was published 89 days ago, on 20 July 2026. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.

Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 30 filings, this issuer sits above that mark. Since 2016, the database holds 20 purchases and 27 sales by insiders of the company.

Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.